PPAR agonists as effective adjuvants for COVID-19 vaccines, by modifying immunogenetics: a review of literature.
Antoine Fakhry AbdelMassihRahma MenshaweyJumana H IsmailReem J HusseinyYousef M HusseinyShenoda YacoubAya KamelRafeef HozaienElaria YacoubEsraa MenshaweyAbanoub AbdelmalekAhmed AbouelazaemAhmed ElhatwAhmed AboelmaatyAlaaelrahman ShahibAmany MansourAya KamalBasant MohamedBemen AtifBeshoy GhabrealCatherine AbdelmalakDavid IbrahimEbtesam ElsaifyFarah MagdyFarid G HannaHadeer HafezHafsa DahirKerlos MerhomMaram AhmedMariam BisharaMina TawfikMina YoussefMohamed El SharnoubyMourad HamoudaMusheera AmmarNada AliNada DanielNadine El-HusseinyNoha AbdelraoufNuran K AbdelhameedRadwa AhmedRadwa OthmanRahma MohamadeinRana AllamRana ElgendyRana SheblSaged ElsherbineySarah FouadSara EmelSara OwaisSarah HettaSamah El-SamanShaimaa AbdelalimSherin GalalYara AsarYara OsmanYasmeen KhalafYoustina AzizYousra KhafagyNervana GamalBiagio CastaldiPublished in: Journal, genetic engineering & biotechnology (2021)
In view of the above, we suggest the use of PPAR as adjuvants to vaccines in general especially the emerging COVID-19 vaccine due to their role in enhancing immunologic memory through DNA-dependent mechanisms.